• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Mixed; Bristol Myers Posts Upbeat Earnings

    10/26/23 9:44:11 AM ET
    $ABVC
    $BETS
    $BMY
    $PXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Restaurants
    Consumer Discretionary
    Get the next $ABVC alert in real time by email

    U.S. stocks traded mixed this morning, following the release of several economic reports.

    Following the market opening Thursday, the Dow traded up 0.10% to 33,069.66 while the NASDAQ fell 0.24% to 12,790.71. The S&P 500 also fell, dropping, 0.13% to 4,181.15.

    Check This Out: Meta To Rally Over 42%? Here Are 10 Top Analyst Forecasts For Thursday

     

    Leading and Lagging Sectors

     

    Real estate shares rose by 1% on Thursday.

    In trading on Thursday, communication services shares dipped by 2%.

     

    Top Headline

     

    Bristol Myers Squibb & Co (NYSE:BMY) reported better-than-expected earnings for its third quarter.

    Bristol Myers Squibb said revenues came in at $10.966 billion, due to lower sales of Revlimid, partially offset by in-line products and its new product portfolio. Analysts were expecting sales of $10.965 billion. Adjusted EPS rose 1% year-over-year to $2.00, beating the consensus of $1.76.

     

    Equities Trading UP

     

    ABVC BioPharma, Inc. (NASDAQ:ABVC) shares shot up 220% to $2.72 after the company announced it entered into a term sheet to license the global rights of CNS drugs with the indications of MDD and ADHD to AiBtl BioPharma at the valuation of $667 million.

    Shares of PaxMedica, Inc. (NASDAQ:PXMD) got a boost, shooting 82% to $0.3146. PaxMedica reported the completion of a type-B meeting with the FDA.

    Appreciate Holdings, Inc. (NASDAQ:SFR) shares were also up, gaining 45% to $0.1751 after falling around 19% on Wednesday. Appreciate Holdings received a notice from Nasdaq regarding delisting.

     

    Equities Trading DOWN

     

    Bit Brother Limited (NASDAQ:BETS) shares dropped 70% to $0.1380 as the company reported pricing of $5.04 million registered direct offering.

    Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) were down 51% to $0.18 as the company announced pricing of $1.7 million public offering of 8.5 million shares of common stock at a price of $0.20 per share.

    Silicom Ltd. (NASDAQ:SILC) was down, falling 29% to $15.82 after the company issued weak sales forecast for the fourth quarter.

    Also Check This Out: Kimberly-Clark, Roblox And 2 Other Stocks Insiders Are Selling

     

    Commodities

     

    In commodity news, oil traded down 2.7% to $83.09 while gold traded down 0.2% at $1,991.20.

    Silver traded down 0.1% to $23.00 on Thursday while copper rose 0.3% to $3.6030.

     

    Euro zone

     

    European shares were lower today. The eurozone’s STOXX 600 fell 0.5%, London’s FTSE 100 fell 0.5% while Spain’s IBEX 35 Index fell 0.5% The German DAX dipped 1% French CAC 40 slipped 0.4%, while Italy’s FTSE MIB Index fell 0.1%.

    The European Central Bank held interest rates during its October meeting. Spain's unemployment rate rose to 11.84% in the third quarter from 11.60% in the prior three-month period. UK car production surged 39.8% year-over-year to 88,230 units in September.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Thursday, with Japan’s Nikkei 225 falling 2.14%, Hong Kong’s Hang Seng Index declining 0.24% and China’s Shanghai Composite Index gaining 0.48%. India’s S&P BSE Sensex, meanwhile, fell around 1.4%.

    Hong Kong’s trade deficit increased to $64.6 billion in September from $44.9 billion in the year-ago month.

     

    Economics

     

    The U.S. economy grew an annualized 4.9% in the third quarter, higher than market expectations of 4.3% and compared to a 2.1% growth in the second quarter.

    U.S. initial jobless claims increased by 10,000 to 210,000 in the week ending Oct. 21, above market estimates of 208,000.

    U.S. durable goods orders rose by 4.7% month-over-month in September versus a 0.1% decline in August and topping market estimates of a 1.7% rise.

    The U.S. trade deficit in goods rose to $85.8 billion in September versus a revised $84.6 billion gap in the prior month.

    Wholesale inventories in the U.S. came in unchanged month-over-month during September, compared to a 0.1% decline in the previous month.

    Now Read This: Top 5 Real Estate Stocks That Could Lead To Your Biggest Gains in October

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $BETS
    $BMY
    $PXMD

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    12/12/2025$62.00Neutral → Buy
    Guggenheim
    Bristol-Myers Squibb Company
    $BMY
    11/13/2025$45.00Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ABVC
    $BETS
    $BMY
    $PXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Bristol-Myers with a new price target

    RBC Capital Mkts initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $60.00

    2/25/26 7:49:08 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers upgraded by UBS with a new price target

    UBS upgraded Bristol-Myers from Neutral to Buy and set a new price target of $65.00

    1/7/26 8:28:35 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

    Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner The Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. "The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options

    4/24/26 6:59:00 AM ET
    $BMY
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

    Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE:BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine's longstanding relationship in advancing biomarker-driven therapies with Bristol Myers Squibb. Homozygous deletion is a major cause of MTAP deficiency.1 Copy number calling can have low signal-to-noise ratio, making the alterations challenging to accurately identify. FoundationOne CDx is a tissue-b

    4/21/26 7:00:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    SEC Filings

    View All

    SEC Form EFFECT filed by Sonoma Pharmaceuticals Inc.

    EFFECT - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    4/24/26 12:15:24 AM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by Sonoma Pharmaceuticals Inc.

    S-1/A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    4/22/26 8:07:01 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Sonoma Pharmaceuticals Inc.

    S-1 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    4/17/26 5:23:53 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Erez Ilan

    3 - SILICOM LTD. (0000916793) (Issuer)

    4/14/26 6:01:42 AM ET
    $SILC
    Computer Communications Equipment
    Telecommunications

    SEC Form 4 filed by Shanahan Karin

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/2/26 4:30:43 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Elkins David V

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/2/26 4:29:24 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SILICOM'S FIRST QUARTER 2026 RESULTS RELEASE SCHEDULED FOR APRIL 30, 2026

    - Conference Call Scheduled for Thursday, April 30, 2026 at 9:00am ET -KFAR SAVA, Israel, March 31, 2026 /PRNewswire/ -- Silicom Ltd. (NASDAQ:SILC), an industry-leading provider of high-performance server/appliances networking solutions, announced today that it will be releasing its first quarter 2026 results on Thursday, April 30, 2026. The Company will be hosting a conference call on that same day at 9:00am Eastern Time. On the call, management will review and discuss the results, and will also be available to answer investors' questions, following the prepared remarks.To participate, investors may either listen via a webcast link hosted on Silicom's website or via the dial-in. The link wi

    3/31/26 8:30:00 AM ET
    $SILC
    Computer Communications Equipment
    Telecommunications

    Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

    Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call. A replay of the webcast will be available here approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol

    3/19/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $BETS
    $BMY
    $PXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Silicom Ltd

    SC 13G - SILICOM LTD. (0000916793) (Subject)

    10/3/24 10:16:11 AM ET
    $SILC
    Computer Communications Equipment
    Telecommunications

    $ABVC
    $BETS
    $BMY
    $PXMD
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

    Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

    5/6/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care